Clinical Features and Natural History of Multiple System Atrophy: A Prospective Multicenter Registry Study in China
Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited. This prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.
• Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or
• Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or
• Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate.
• Age between 40 and 75 years.
• Ability to provide informed consent or availability of a legally authorized representative when applicable.